If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Thursday broker round-up

Thu, 04th Aug 2016 11:59
(ShareCast News) - Next: Goldman Sachs reiterates sell with a target price of 4800p.Standard Chartered: JP Morgan maintains overweight with a 800p target.Shire: JP Morgan reiterates overweight with a 6300p target.Genus: HSBC stays at buy with a 2200p target.Nichols: UBS keeps at buy with a target price of 1525p.Astrazeneca: Jefferies reiterates hold with a target price of 5050p.Direct Line Group: Berenberg keeps at hold with a 406p target.Devro: HSBC reiterates hold with a target of 285p.Rio Tinto: JP Morgan stays at overweight with a 3050p target.Ferrexpo: Jefferies reiterates underperform, 30p target.Victrex: UBS stays at neutral with a 1510p target. Astrazeneca Rio Tinto Victrex Genus Standard Chartered Next Nichols plc

Shares in this article

Related News

WINNERS & LOSERS: JD Sports continues to fall; Close Brothers climbs
19 mins ago

WINNERS & LOSERS: JD Sports continues to fall; Close Brothers climbs

(Alliance News) - The following are the leading risers and fallers among FTSE 100 and 250 index constituents on Friday.

LONDON MARKET CLOSE: FTSE 100 up as US jobs data eases rate hike fears
18 hours ago

LONDON MARKET CLOSE: FTSE 100 up as US jobs data eases rate hike fears

(Alliance News) - European stocks soared on Thursday as weaker than expected US jobs figures dampened market worries of a near-term interest rate hike...

Market News BAE Systems + 15 more shares
Hutchmed drug approved in China for advanced gastric cancer
20 hours ago

Hutchmed drug approved in China for advanced gastric cancer

(Alliance News) - Hutchmed China Ltd on Thursday announced regulatory approval for savolitinib, brand name 'ORPATHYS', for a form of gastric cancer wi...

Pharmaceuticals Hutchmed + 1 more share